Ｃ型慢性肝炎に対するｐｅｇｙｌａｔｅｄ　ｉｎｔｅｒｆｅｒｏｎ　α－２ｂ／ｒｉｂａｖｉｒｉｎ併用療法の無効・再燃例におけるｐｅｇｙｌａｔｅｄ　ｉｎｔｅｒｆｅｒｏｎ　α－２ａ／ｒｉｂａｖｉｒｉｎ併用療法の効果

DOI Web Site Web Site 参考文献9件

書誌事項

タイトル別名
  • Efficacy of peginterferon alfa-2a plus ribavirin for chronic hepatitis C patients who relapsed or did not respond to pre-treatment with peginterferon alfa-2b plus ribavirin
  • Cガタ マンセイ カンエン ニ タイスル pegylated interferon アルファ 2b ribavirin ヘイヨウ リョウホウ ノ ムコウ サイネンレイ ニ オケル pegylated interferon アルファ 2a ribavirin ヘイヨウ リョウホウ ノ コウカ

この論文をさがす

抄録

We investigated the efficacy of peginterferon alfa-2a plus ribavirin (α-2a therapy) for chronic hepatitis C patients who relapsed or did not respond to peginterferon alfa-2b plus ribavirin (α-2b therapy). Eleven patients with relapse and 5 non-responders to α-2b therapy received α-2a therapy for 48 to 72 weeks. In those with relapse, the rate of RVR, complete EVR and SVR were 54.5%, 72.7% and 72.7%, respectively. In non-responders, the rate of RVR, complete EVR and SVR were all 0%. Three of 5 LVR patients on α-2b therapy achieved SVR on α-2a therapy. Our findings suggest that patients showing relapse on α-2b therapy could achieve an early viral response and high SVR rate on α-2a therapy, non-responders could not.<br>

収録刊行物

  • 肝臓

    肝臓 52 (4), 251-254, 2011

    一般社団法人　日本肝臓学会

参考文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ